CRH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRH is not a clear buy right now for a beginner long-term investor who wants to deploy capital immediately. The stock has solid long-term business quality and supportive analyst sentiment, but the current technical setup is weak and the options sentiment is mixed-to-bearish. With no Intellectia buy signals today, I would hold off on a new purchase at this exact level and wait for a better entry.
CRH is currently trading at 112.81, slightly above the prior close of 112.63, but the broader tape remains weak after a -1.98% regular-session move. MACD histogram is negative and expanding, which points to downward momentum. RSI_6 at 43.15 is neutral but leaning weak, so there is no strong oversold buy signal. Moving averages are converging, suggesting a possible inflection point, but not a confirmed uptrend. Price is sitting just above support at 111.18 and below pivot at 114.69, meaning the stock is still in a fragile short-term position.
["Hedge funds are buying, with buying activity up 168.58% over the last quarter.", "Analyst sentiment remains constructive overall, with multiple Overweight/Buy ratings.", "Wells Fargo recently upgraded CRH to Overweight, citing valuation and saying Europe risks are overly priced in.", "The company announced an agreement to acquire Axius Water, a potential growth catalyst.", "Q1 revenue grew 9.09% YoY, showing healthy top-line momentum."]
["Recent price action is weak, with a notable regular-session decline and negative MACD momentum.", "Options positioning is bearish-ish, with put-call ratios above 1.0.", "The stock is trading below the pivot level, indicating limited near-term technical strength.", "Net income remains negative in the latest quarter, despite improvement.", "Historical pattern analysis suggests a negative drift over the next day, week, and month."]
In Q1 2026, CRH posted revenue of $7.37B, up 9.09% year over year, which is a solid growth trend for the latest quarter season. Gross margin improved to 27.75%, up 2.06% YoY, showing better profitability at the gross level. Net income was still negative at -$176M, but improved 74.26% YoY, and EPS also improved to -0.26 from prior weakness. This indicates improving operating performance, but profitability is not yet fully established.
Wall Street sentiment is broadly positive. JPMorgan, Morgan Stanley, and BofA all kept bullish ratings and recent price targets around the $135-$143 range, while Wells Fargo upgraded the stock to Overweight. Some targets were trimmed slightly, but the overall stance remains constructive. The pros view is that CRH has valuation support, improving estimates, and resilience despite macro risk. The cons view is that Europe-related risk and earnings uncertainty still limit conviction, and one firm remains Neutral.
